AI Article Synopsis
- * A patient with ALK-positive lung adenocarcinoma took crizotinib through nasogastric and PEG tubes, leading to positive treatment results.
- * This case suggests that crizotinib can be administered via these alternative methods, providing a viable treatment option for patients with poor prognoses in ALK-positive NSCLC.
Article Abstract
Crizotinib-an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-is effective in non-small-cell lung cancers (NSCLCs) that express ALK. Here, we report a patient with ALK-positive lung adenocarcinoma who was administered crizotinib via nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes, with positive results. This case indicates that patients with ALK-positive NSCLC may successfully be treated with crizotinib via nasogastric or PEG tubes. This approach can even be used as a salvage treatment in patients with poor prognoses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.resinv.2012.12.001 | DOI Listing |
Publication Analysis
Top Keywords
nasogastric percutaneous
8
percutaneous endoscopic
8
endoscopic gastrostomy
8
crizotinib nasogastric
8
peg tubes
8
crizotinib administered
4
administered nasogastric
4
gastrostomy tubes
4
tubes successful
4
successful treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!